Patent · US Active

Oligonucleotides for SARS-CoV-2 modulation

US12077758B2 · kind B2 · utility

0Cited by

14References

18Claims

0Family size

Assignee

University of Massachusetts · US

Inventors

Anastasia Khvorova · Boulder, US
Jonathan K. Watts · Worcester, US
Zachary Kennedy · Richland, US
Annabelle Biscans · Cambridge, US
Bruno Miguel da Cruz Godinho · Worcester, US
Chantal Ferguson · Worcester, US
Dimas Echeverria Moreno · Worcester, US
Ken Yamada · Brookline, US
Daniel O′Reilly · Boston, US
Kathryn Monopoli · Boston, US
Vignesh Narayan Hariharan · Natick, US
Qi Tang · Boston, US
Sarah Davis · Carlsbad, US
Samuel Hildebrand · Boston, US
Socheata Ly · Boston, US
Minwook Shin · Boston, US
Pranathi Meda Krishnamurthy · Boston, US
Nicholas McHugh · Boston, US
Jacquelyn Sousa · Boston, US
Jillian Caiazzi · Boston, US
Yann Thillier · Boston, US
Gitali Devi · Boston, US

Key dates

Filing date	May 28, 2021
Grant date	Sep 3, 2024
Priority date	—
Expiry date	May 28, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21075
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.